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Abstract 
Patients experiencing several cancers can be a challenge, as optimal treatment options 
for the different cancers might interfere with each other. In this case report, we present a 
woman diagnosed with 4 different types of cancer. She was treated with surgery, 
chemotherapy and radiotherapy. Her performance status was generally good, and she 
tolerated the treatment very well, except some troublesome side effects in the thoracic 
soft tissue after stereotactic body radiotherapy. 
 
Case Report 
A 65-year-old woman with a smoking history of about 45 pack-years was referred to our clinic. In 
1986, she had been treated for a cervical cancer stadium T2b with intracavitary brachytherapy and 
external radiation of the pelvis up to 50 Gy. Apart from chronic urge incontinence, she had developed 
no acute or late toxicity after radiotherapy. Controls showed no sign of relapse. In November 2007, she 
was diagnosed with a stage I, node-negative breast cancer. In preparation of adjuvant radiotherapy after 
breast-conserving surgery, a chest X-ray showed two pulmonary nodules, one in the right upper lobe 
and one in the left upper lobe. By that time, she was in good performance status, had no pulmonary 
symptoms and no weight loss. Physical examination revealed no pathological findings. 
Thoracic CT scan showed a 29 × 30 × 25 mm spiculated lesion in the right upper lobe. In the left 
upper lobe, a conflating lesion of 15 × 19 × 8 mm was detected. There was no mediastinal 
lymphadenopathy. None of the lesions were in range for bronchoscopic biopsy, but CT-guided biopsy 
of the nodule in the right lung was performed. A poorly differentiated squamous cell carcinoma was 
diagnosed and the limited biopsy material showed positive staining for CK 7, 5 and 6, BerEP4 and 
TTF1. The pathologists could not definitely conclude if it was a primary lung carcinoma or a relapse 
from her cervical cancer. The postoperative radiotherapy to the breast was cancelled.  
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After interdisciplinary discussion, it was decided to start combination chemotherapy with topotecan 
and cisplatin, as the tumour was considered a cervical cancer metastasis. After 6 cycles with moderate 
toxicity, CT revealed that the nodule in the left lung was no longer apparent. Unfortunately, there was a 
significant growth of the lesion in the right lung, and a 18FDG-PET/CT showed intense metabolic 
activity with high uptake of FDG in the tumour with a standardised uptake value (SUV) of 34 (fig. 1). 
Surprisingly, pathological uptake in a nodule in the proximal rectum with an SUV of 12 was also found. 
MRI of the pelvis was performed and a colonoscopy with biopsy verified a highly differentiated 
adenocarcinoma in the sigmoideum, staged as Duke A. The patient underwent an abdominal 
rectosigmoid resection and colorectal anastomosis. 
Due to the inconclusive histopathological evaluation of the tumour in the right upper lobe, the 
limited effect of chemotherapy, and the radiological consistence with primary lung cancer, it was 
concluded that this tumour most likely was a primary lung carcinoma, and a radical approach was 
recommended. Due to chronic obstructive pulmonary disease, the patient had severe reduction of lung 
function, excluding her from thoracic surgery and conventional radiotherapy. The only remaining 
curative alternative was a high-dose stereotactic body radiotherapy (SBRT) for her primary T2a lung 
cancer. In December 2008, the patient underwent a 4-dimensional CT-gated SBRT against the lesion in 
the right upper lobe (fig. 2). SBRT was performed to a total dose of 45 Gy, delivered in 3 fractions given 
every other day. Image guidance with on-board CT scan was performed to re-localize the target lesion 
before every treatment delivery. The patient accomplished treatment without acute toxicity. 
Six weeks after SBRT, the patient presented with intense thoracic pain requiring moderate morphine 
doses, chest wall oedema and fever. CT scan showed significant tumour reduction from 29 × 30 ×  
25 mm to 20 × 22 × 18 mm, consolidating lung parenchyma and atelectasis due to stricture of a segment 
bronchus and a pronounced thoracic oedema. These early complications after high-dose stereotactic 
radiotherapy are well documented, but are rare in this intensity [1]. The solid swelling over the right 
chest wall corresponded to the radiation field. In order to eliminate the possibility of a relapse, biopsies 
were taken, showing inflammatory tissue without evidence of atypical cells. After treatment with 
corticosteroids, nonsteroidal anti-inflammatory drugs and morphine for 3 months, the clinical and 
radiological alterations reversed and medication could be reduced. PET-CT showed a markedly 
inflammatory response in the chest wall without uptake suspicious of malignancy. The patient was 
followed up with alternating CT scans and PET-CT every 3 months, and a total regression of the clinical 
symptoms was registered after 1 year (fig. 3). One and a half year after SBRT, she was without clinical or 
metabolic indicators of tumour activity. Nevertheless, a minor chest wall oedema and mild lung fibrosis 
around the high-dose area without clinical impact could be verified. 
Discussion 
Multiple synchronous or metachronous malignancies are not rare. Estimates between 
0.73 and 11.7% are published [2]. Treating a patient with multiple malignancies can be 
challenging. Previous treatment with surgery, chemotherapy and radiation therapy can 
lead to severe comorbidity that may have an impact on further possibilities of effective 
cancer treatment. The technological development in radiotherapy has undergone an era 
of unprecedented transformation, allowing the precise and non-invasive administration 
of high radiation doses in an aggressive, decisive manner to eradicate a discrete focus of 
cancer, and has opened a new treatment option for patients who formerly had no curative 
alternative. High-dose SBRT for early-stage lung cancer is a well-established, well-
documented and safe approach [3–5].  
Acute pneumonitis or fibrosis is regularly seen radiographically after SBRT, but such 
findings are usually without clinical relevance even though many patients undergoing 
SBRT have reduced lung function. In our case, acute pneumonitis and stricture of a 
segment bronchus with consecutive atelectasis developed already 6 weeks after SBRT and 
diminished after 1 year. These pulmonary side effects had no clinical impact on the 
patient’s everyday life. Studies measuring pulmonary function before and after treatment 
with SBRT have not shown permanent declines in function [4]. Skin erythema, fractures 
of the ribs, vertebral body, chest wall inflammation, and acute and chronic chest pain are  
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side effects that may appear in high-dose areas. For chronic chest pain and rib fracture 
after SBRT, a dose-response correlation and a dose-volume relationship are well 
documented [6, 7]. In our patient, the dose per fraction to 2 cm
3 of the rib was 13.9 Gy 
and the volume of the chest wall receiving >30 Gy was 67 cm
3. Both values exceeded the 
recommended doses by factor 1.5 and 2.2. These findings may explain our patient’s chest 
wall toxicity. In SBRT, the type of side effects depends on the tumour location. The 
minimum distance from our patient’s lesion to the chest wall was only 25 mm, which 
unavoidably gives a high dose contribution to the chest wall. Chronic chest pain is also a 
common problem after thoracic surgery in up to 10% of patients, and the response to 
treatment is poor [8]. Our patient’s soft tissue reaction could be influenced by the radio-
sensitizing effect of cisplatin [9–11]. Even if the time interval between chemotherapy and 
SBRT in our patient was 5 months, one can speculate about a contributing effect of 
cisplatin on the excessive soft tissue reaction after SBRT. This theory is supported by the 
fact that our patient had tolerated high doses given to the pelvis in 1986. A third option is 
that she is genetically susceptible to cancer and to radiotherapeutic side effects due to her 
genetic characteristics involved in DNA repair. Our knowledge about the genetics 
underlying differences in normal tissue radiosensitivity is still sparse, and there are no 
obvious candidate genes identified [12]. 
Our case illustrates some of the challenges and possibilities of modern cancer 
treatment. After diagnosed with cancer for the first time, our patient has survived 4 life-
threatening cancer diagnoses. She is in excellent condition and according to her, she has 
more courage to face life than ever. 
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Fig. 1. PET-CT of the tumour in the right lung. 
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Fig. 2. Radiation field in the planning CT prior to SBRT. 
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Fig. 3. Thoracic PET-CT showing inflammation after SBRT. 
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